Like Kymera, I am not prepared to give up on the protein deg story yet, and although a poor set of data, or the exit of Sanofi from the KT-474 program could derail the company's share price ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Kymera's partnership with Sanofi includes potential milestone payments of up to $1.48 billion for IRAK4 program. Find out the reasons to rate KYMR stock a Buy.

Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.

Sanofi has informed Kymera that it will advance KT-485, Kymera's drug candidate targeting IRAK4 for immuno-inflammatory diseases, into clinical studies and not proceed with KT-474.

Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical ...

Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.